September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
September 2022 in “Journal of Sulaimani Medical College” The combination treatment showed some improvement but wasn't significantly better than using betamethasone valerate alone.
83 citations
,
August 2020 in “Resources” Macroalgae compounds offer sustainable, effective benefits for cosmetics.
70 citations
,
August 2019 in “European Journal of Medicinal Chemistry” 26 citations
,
February 2015 in “Pediatric blood & cancer” Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
23 citations
,
March 2017 in “JAAD case reports” The document suggests a possible link between FAM111B gene mutations and increased cancer risk, particularly pancreatic cancer.
17 citations
,
December 2022 in “Biosensors” Triboelectric nanogenerators can power wearable medical devices for long-term self-treatment and monitoring.
15 citations
,
January 2015 in “Dermatitis” Topical immunotherapy is the best treatment for severe alopecia areata.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
12 citations
,
May 2015 in “Journal of the National Comprehensive Cancer Network” Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
2 citations
,
June 2024 in “Journal of Clinical Medicine” Alopecia Areata can affect nails, often improving on its own, but JAK inhibitors may help.
1 citations
,
August 2025 in “Medicina” Non-invasive imaging techniques improve scalp condition diagnosis and patient quality of life.
1 citations
,
November 2024 in “JAAD reviews.” Patients with alopecia areata prefer effective, safe, and convenient treatments, especially topical ones.
1 citations
,
January 2024 in “Updates in clinical dermatology”
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
June 2026 in “Wiener klinische Wochenschrift” New treatments for alopecia areata show promise but need ongoing use and have infection risks.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
February 2026 in “International Journal of Dermatology” Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
January 2026 in “British Journal of Health Psychology” Alopecia affects self-confidence, body image, and social interactions, causing distress and requiring better support and awareness.
January 2026 in “Case Reports in Dermatological Medicine” Lichen Planus in siblings may be influenced by genetics and environment.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
September 2025 in “Value in Health” August 2025 in “Frontiers in Immunology” Primary cicatricial alopecia is linked to various health issues, indicating broader systemic problems.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
April 2025 in “International Journal of Molecular Sciences” New treatments for hair loss show promise with advanced therapies and better targeting.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.